Literature DB >> 2675619

In vivo immunohistochemical identification of tumor necrosis factor/cachectin in human lymphoid tissue.

J L McCall1, K Yun, S Funamoto, B R Parry.   

Abstract

To find an alternative approach to the in vivo detection of tumor necrosis factor/cachectin (TNF alpha), an immunohistochemical method to identify TNF alpha in histologic sections was developed. This method employs the streptavidin-biotin immunoperoxidase technique, and TNF alpha-specific monoclonal and polyclonal antibodies, on cryostat sections of fresh frozen human lymphoid tissue. Staining was evident in most specimens displaying follicular hyperplasia, but was absent from histologically normal tissue. Both tingible body macrophages and follicular dendritic reticulum cells appeared from phenotype analysis in serial sections and by double staining experiments to constitute the main source of TNF alpha. This technique complements other systemically oriented assays that may fail to detect significant in vivo TNF alpha production and activity at a cellular level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2675619      PMCID: PMC1879868     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

Review 1.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 2.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

3.  Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.

Authors:  D F Jelinek; P E Lipsky
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

4.  An improved method for the inhibition of endogenous peroxidase non-deleterious to lymphocyte surface markers. Application to immunoperoxidase studies on eosinophil-rich tissue preparations.

Authors:  S M Andrew; B Jasani
Journal:  Histochem J       Date:  1987-08

5.  Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.

Authors:  B B Aggarwal; T E Eessalu; P E Hass
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

6.  Presence of tumour necrosis factor or a related factor in human basophil/mast cells.

Authors:  M Steffen; M Abboud; G K Potter; Y P Yung; M A Moore
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

7.  Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from true histiocytic malignancies.

Authors:  S M Hsu; X Zhao
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

8.  Human dendritic cells and macrophages. In situ immunophenotypic definition of subsets that exhibit specific morphologic and microenvironmental characteristics.

Authors:  G S Wood; R R Turner; R A Shiurba; L Eng; R A Warnke
Journal:  Am J Pathol       Date:  1985-04       Impact factor: 4.307

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  Effect of tumor necrosis factor alpha on mitogen-activated human B cells.

Authors:  J H Kehrl; A Miller; A S Fauci
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more
  9 in total

1.  Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha.

Authors:  B Ryffel; M Brockhaus; U Dürmüller; F Gudat
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

2.  Tumour necrosis factor receptor distribution in human lymphoid tissue.

Authors:  B Ryffel; M Brockhaus; B Greiner; M J Mihatsch; F Gudat
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

3.  Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy.

Authors:  S Ohshima; Y Saeki; T Mima; M Sasai; K Nishioka; H Ishida; M Shimizu; M Suemura; R McCloskey; T Kishimoto
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

4.  An immunohistochemical method for the detection of tumour necrosis factor alpha in cytospins of human bronchoalveolar lavage cells.

Authors:  S Hamilton; M Healy; P Corris; R Scott
Journal:  Histochem J       Date:  1995-06

5.  Localization of tumour necrosis factor production in cells at the materno/fetal interface in human pregnancy.

Authors:  G Vince; S Shorter; P Starkey; J Humphreys; L Clover; T Wilkins; I Sargent; C Redman
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

6.  Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.

Authors:  L P Ruco; D Pomponi; R Pigott; A Stoppacciaro; F Monardo; S Uccini; D Boraschi; A Tagliabue; A Santoni; E Dejana
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

7.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  Analysis of tumour necrosis factor alpha-specific, lactose-specific and mistletoe lectin-specific binding sites in human lung carcinomas by labelled ligands.

Authors:  K Kayser; H J Gabius; S Gabius; O Hagemeyer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

9.  Disturbed follicular architecture in B cell A disintegrin and metalloproteinase (ADAM)10 knockouts is mediated by compensatory increases in ADAM17 and TNF-α shedding.

Authors:  Lauren Folgosa; Hannah B Zellner; Mohey Eldin El Shikh; Daniel H Conrad
Journal:  J Immunol       Date:  2013-11-13       Impact factor: 5.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.